GUTS
Fractyl Health, Inc. Common Stock NASDAQ Listed Feb 2, 2024$0.83
-4.83%
vs $0.87
Mkt Cap $62.7M
52w Low $0.39
22.0% of range
52w High $2.37
50d MA $0.74
200d MA $1.09
P/E (TTM)
-0.5x
EV/EBITDA
—
P/B
6.6x
Debt/Equity
6.5x
ROE
-1490.3%
P/FCF
-0.7x
RSI (14)
53.50
ATR (14)
$0.07
Beta
1.19
50d MA
$0.74
200d MA
$1.09
Avg Volume
2.3M
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
CIK (SEC)
Phone
781-902-8800
17 Hartwell Avenue · Lexington, MA 02421 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.19 | 0.15 | +178.9% | 0.43 | +13.8% | +16.2% | -5.4% | -5.2% | -4.8% | +7.2% | — |
| Nov 12, 2025 | AMC | -0.34 | -0.35 | -2.9% | 1.13 | +11.5% | -0.9% | +12.5% | +13.5% | -2.1% | -5.0% | — |
| Aug 12, 2025 | AMC | -0.37 | -0.53 | -43.2% | 0.98 | +0.1% | +2.7% | -3.2% | +4.4% | -1.0% | -1.9% | — |
| May 13, 2025 | AMC | -0.49 | -0.49 | +0.0% | 1.77 | -4.0% | -13.0% | +7.1% | +2.4% | +25.4% | -0.9% | — |
| Mar 3, 2025 | AMC | -0.44 | -0.52 | -18.2% | 1.56 | -5.1% | -3.8% | +6.0% | -1.3% | -10.2% | +1.4% | — |
| Nov 12, 2024 | AMC | -0.50 | -0.48 | +4.0% | 2.43 | +0.8% | -2.5% | -11.8% | -5.7% | +4.6% | +6.3% | — |
| Aug 14, 2024 | AMC | -0.46 | -0.36 | +21.7% | 2.23 | +3.1% | +5.4% | +1.7% | +13.8% | +5.9% | +4.2% | — |
| May 13, 2024 | AMC | -0.30 | -0.75 | -150.0% | 6.10 | +2.8% | +8.5% | +8.0% | -6.4% | +5.5% | -1.3% | — |
| Apr 1, 2024 | AMC | -0.65 | -8.02 | -1133.8% | 7.45 | -5.0% | -9.5% | +9.1% | +1.8% | -1.6% | +3.8% | — |
| Sep 30, 2023 | AMC | — | -0.33 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.63 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.25 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.58 | $0.59 | +1.5% | +6.7% | +5.3% | +0.5% | -8.3% | +5.9% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.50 | $0.48 | -4.2% | -5.4% | -5.2% | -4.8% | +7.2% | +1.5% |
| Jan 30 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $0.58 | $0.57 | -3.1% | -21.4% | +2.7% | -5.3% | -4.9% | -6.0% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.55 | -0.6% | +17.9% | +4.3% | +3.1% | +3.0% | +9.3% |
| Nov 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.29 | $1.32 | +2.3% | +8.5% | +4.3% | +0.0% | +1.4% | +6.1% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.01 | $1.20 | +18.8% | +32.7% | +11.9% | +6.0% | -7.5% | +6.8% |
| Aug 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.01 | $0.98 | -2.9% | -3.2% | +4.4% | -1.0% | -1.9% | -1.1% |
| Feb 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1.84 | $1.78 | -3.3% | -7.6% | -9.4% | +6.5% | -1.8% | -6.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Royan Ajay | — | Buy | 23,000 | $0.85 | $20K | 40,901 | -8.71% | -4.83% |
| Jun 10, 2026 | Rajagopalan Harith | Chief Executive Officer | Buy | 25,000 | $0.73 | $18K | 540,557 | +17.42% | +0.98% |
| Jun 10, 2026 | Sheffield Ian | — | Buy | 35,000 | $0.73 | $26K | 35,000 | +17.42% | +0.98% |
| Jun 10, 2026 | BRADLEY WILLIAM | — | Buy | 68,493 | $0.73 | $50K | 84,622 | +17.42% | +0.98% |
| Jun 8, 2026 | Smith Weber Lara | Chief Financial Officer | Buy | 20,000 | $0.69 | $14K | 20,000 | +10.19% | -8.71% |
8-K · 8.01
!! High
Fractyl Health, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 4
8-K · 7.01
! Medium
Fractyl Health, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 11
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
GUTS disclosed non-material information under Regulation FD with limited liability, suggesting management communication that doesn't constitute official guidance and carries no legal consequences for accuracy.
Mar 24
8-K
Unknown — 8-K Filing
GUTS faces potential Nasdaq delisting due to minimum bid price violation, requiring a reverse stock split to regain compliance, which would dilute existing shareholders and signal financial distress.
Mar 17
8-K · 7.01
! Medium
Fractyl Health, Inc. -- 8-K 7.01: Regulation FD Disclosure
Fractyl Health completed enrollment in its REMAIN-1 pivotal trial for Revita's weight maintenance indication, advancing its clinical pipeline with 2026 regulatory milestones ahead while maintaining cash guidance.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Silverarc Capital Management, Llc | 9,840,041 | $22M | Reduced | Dec 2025 |
| 2 | Deer Management Co. Llc | 4,770,901 | $10M | — | Dec 2025 |
| 3 | Jane Street Group, Llc | 1,862,600 | $4M | New | Dec 2025 |
| 4 | Morgan Stanley | 1,312,964 | $3M | Added | Dec 2025 |
| 5 | Vanguard Capital Management Llc | 5,533,006 | $3M | New | Mar 2026 |
| 6 | Maverick Capital Ltd | 3,974,806 | $2M | Reduced | Mar 2026 |
| 7 | Cm Management, Llc | 800,000 | $2M | Added | Dec 2025 |
| 8 | Woodline Partners Lp | 2,241,679 | $1M | Reduced | Mar 2026 |
| 9 | M28 Capital Management Lp | 1,856,117 | $850K | — | Mar 2026 |
| 10 | Ubs Group Ag | 1,622,163 | $743K | Added | Mar 2026 |
| 11 | Hudson Bay Capital Management Lp | 171,816 | $378K | New | Dec 2025 |
| 12 | Marshall Wace, Llp | 807,796 | $372K | Reduced | Mar 2026 |
| 13 | Two Sigma Investments, Lp | 479,737 | $220K | Reduced | Mar 2026 |
| 14 | Hightower Advisors, Llc | 51,442 | $113K | — | Dec 2025 |
| 15 | Northern Trust Corp | 215,877 | $99K | — | Mar 2026 |
| 16 | Peak6 Llc | 200,000 | $92K | — | Mar 2026 |
| 17 | Commonwealth Equity Services, Llc | 38,700 | $85K | New | Dec 2025 |
| 18 | Susquehanna International Group, Llp | 176,087 | $81K | Reduced | Mar 2026 |
| 19 | Citigroup Inc | 35,076 | $77K | Added | Dec 2025 |
| 20 | Bank Of America Corp /de/ | 124,989 | $57K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 527,317 | $247K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 319,523 | $146K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 214,366 | $101K | Feb 2026 |
| 4 | Ultra-Small Company Market Fund | 208,925 | $96K | Mar 2026 |
| 5 | Fidelity Series Total Market Index Fund | 181,077 | $85K | Feb 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 104,682 | $49K | Feb 2026 |
| 7 | Victory Extended Market Index Fund | 12,374 | $6K | Jan 2026 |
Valuation
Market Cap
$62.7M
Enterprise Value
$11.7M
P/E (TTM)
-0.48x
Forward P/E
—
PEG Ratio
-0.08x
P/B
6.63x
P/S
—
P/FCF
-0.69x
EV/EBITDA
—
Shares Out
75.8M
Financials (TTM)
Revenue
$0
Net Income
-$108.0M
EBITDA
-$106.9M
Free Cash Flow
-$90.9M
Op Cash Flow
-$90.3M
EPS Basic
$-1.86
EPS Diluted
$-1.74
EPS Forward
$-0.65
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$121.4M
Total Liab.
$111.9M
Total Equity
$9.5M
Cash
$81.5M
LT Debt
$30.6M
Book Value/Sh
$0.12
Debt/Equity
6.52x
Current Ratio
4.78
Quick Ratio
4.78
Returns & Growth
ROE
-1490.3%
ROA
-116.1%
ROIC
-89.5%
Rev Growth YoY
-100.0%
EPS Growth YoY
-14.8%
Price Returns
2W
-15.5%
1M
+26.5%
3M
+71.8%
6M
-48.6%
12M
-57.6%
Technicals
52W High
$2.37
52W Low
$0.39
50d MA
$0.74
200d MA
$1.09
RSI (14)
53.50
ATR (14)
$0.07
Beta
1.19
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.00
High
$8.00
Low
$2.00
Median
$5.00
Data updated apr 25, 2026 12:43pm
· Source: financialmodelingprep.com